CTOR Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of -- compared to Citius Oncology's net margin of -55.52%. Citius Oncology's return on equity of -- beat Ardelyx's return on equity of -34.68%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 91.08%. On the other hand Ardelyx has an analysts' consensus of $10.91 which suggests that it could grow by 137.15%. Given that Ardelyx has higher upside potential than Citius Oncology, analysts believe Ardelyx is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Ardelyx quarterly revenues of $74.1M. Citius Oncology's net income of -$7.7M is higher than Ardelyx's net income of -$41.1M. Notably, Citius Oncology's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 3.01x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Citius Pharmaceuticals has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Citius Pharmaceuticals's return on equity of --.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 91.08%. On the other hand Citius Pharmaceuticals has an analysts' consensus of $6.00 which suggests that it could grow by 302.69%. Given that Citius Pharmaceuticals has higher upside potential than Citius Oncology, analysts believe Citius Pharmaceuticals is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Pharmaceuticals has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.767%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Citius Pharmaceuticals pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Citius Pharmaceuticals quarterly revenues of --. Citius Oncology's net income of -$7.7M is higher than Citius Pharmaceuticals's net income of -$10.9M. Notably, Citius Oncology's price-to-earnings ratio is -- while Citius Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus -- for Citius Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -- compared to Citius Oncology's net margin of -486.44%. Citius Oncology's return on equity of -- beat Nektar Therapeutics's return on equity of -201.73%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 91.08%. On the other hand Nektar Therapeutics has an analysts' consensus of $94.83 which suggests that it could grow by 292.85%. Given that Nektar Therapeutics has higher upside potential than Citius Oncology, analysts believe Nektar Therapeutics is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.928%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $10.5M. Citius Oncology's net income of -$7.7M is higher than Nektar Therapeutics's net income of -$50.9M. Notably, Citius Oncology's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 3.87x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -- compared to Citius Oncology's net margin of 4.19%. Citius Oncology's return on equity of -- beat TG Therapeutics's return on equity of 19.78%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 91.08%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that Citius Oncology has higher upside potential than TG Therapeutics, analysts believe Citius Oncology is more attractive than TG Therapeutics.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Citius Oncology's net income of -$7.7M is lower than TG Therapeutics's net income of $5.1M. Notably, Citius Oncology's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.